Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study
Cephalalgia · 2024
DOI: 10.1177/03331024241233979 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Cephalalgia, 2024. Verfasst von Marta Pascual-Mato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqué…. Hauptthemen laut MEDLINE: Migraine Disorders, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Some studies have suggested an association between migraine and inflammatory bowel disease. We determined migraine prevalence in a cohort of patients with inflammatory bowel disease.
Methods
Patients with inflammatory bowel disease aged 18–65 years were interviewed using an ad hoc headache questionnaire. Those who admitted a history of headache in the last year answered the three questions of the ID-Migraine questionnaire. Those who answered “yes” to the three of them were classified as “definite” and those who answered “yes” to two were classified as “probable” migraine.
Results
We interviewed 283 patients with inflammatory bowel disease. Of these, 176 (62.2%) had headache. Fifty-nine (20.8%; 95% CI 16.3–26.0%) met migraine criteria either definite (n = 33; 11.7%; 95% CI 8.2–16.0%) or probable (n = 26; 9.2%; 95% CI 6.1–13.2). When divided by gender, 12 men (9.6%; 95% CI 5.1–16.2%) and 47 women (29.8%; 95% CI 22.8–37.5%) met migraine criteria. The prevalence of migraine was increased in inflammatory bowel disease patients from the current cohort (20.8%) versus that reported for our general population for the same age group (12.6%; p < 0.0001). These differences remained significant in female inflammatory bowel disease patients (29.8% versus 17.2% in our general population; p < 0.0001), but not in males (9.6% in inflammatory bowel disease vs 8.0%; p = 0.30). Seventeen patients with inflammatory bowel disease (6.0%; 95% CI 3.54–9.44%) fulfilled chronic migraine criteria. There were no differences in migraine prevalence by inflammatory bowel disease subtypes.
Conclusion
Migraine prevalence, including chronic migraine, seems to be increased in patients with inflammatory bowel disease. The fact that this association was stronger for women suggests an influence of sex-related factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain.
- Service of Neurology; University Hospital Marqués de Valdecilla, Universidad de Cantabria and IDIVAL, Santander, Spain.
ORCID-Profile: Julio Pascual
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Pascual-Mato, M., Gárate, G., de Prado-Tejerina, C., García, M. J., Castro, B., González-Quintanilla, V., Madera, J., Crespo, J., Pascual, J., & Rivero, M. (2024). Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study. Cephalalgia. https://doi.org/10.1177/03331024241233979
Vancouver
Pascual-Mato M, Gárate G, de Prado-Tejerina C, García MJ, Castro B, González-Quintanilla V, et al. Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study. Cephalalgia. 2024. doi:10.1177/03331024241233979
BibTeX
@article{PascualMato2024,
author = {Pascual-Mato, Marta and Gárate, Gabriel and de Prado-Tejerina, Carlota and García, María José and Castro, Beatriz and González-Quintanilla, Vicente and Madera, Jorge and Crespo, Javier and Pascual, Julio and Rivero, Monserrat},
title = {Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241233979}
}
EUVIMED